Chikungunya Fever – Pipeline Review, H1 2020

Global Markets Direct’s, ‘Chikungunya Fever – Pipeline Review, H1 2020’, provides an overview of the Chikungunya Fever pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Chikungunya Fever, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Chikungunya Fever and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Chikungunya Fever

– The report reviews pipeline therapeutics for Chikungunya Fever by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Chikungunya Fever therapeutics and enlists all their major and minor projects

– The report assesses Chikungunya Fever therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Chikungunya Fever

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Chikungunya Fever

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Chikungunya Fever pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Activirosomes Ltd

Bharat Biotech Ltd

Bow Therapeutics

Ciloa

Clayton Biotechnologies Inc

Emergent BioSolutions Inc

Emergex Vaccines Ltd

Ennaid Therapeutics LLC

Etubics Corp

Hawaii Biotech Inc

HSRx Group

Immunomodulation Inc

Imophoron Ltd

Indian Immunologicals Ltd

Inovio Pharmaceuticals Inc

Integral Molecular Inc

Integrated BioTherapeutics Inc

Medigen Inc

Moderna Inc

Najit Technologies Inc

Pai Life Sciences Inc

Paradigm Biopharmaceuticals Ltd

Precision Virologics Inc

Profectus BioSciences Inc

ProtInhi BV

Riboscience LLC

Ridgeback Biotherapeutics LP

Sementis Ltd

Shionogi & Co Ltd

Takeda Pharmaceutical Co Ltd

Themis Bioscience GmbH

Valneva SE

Vaxart Inc

VenatoRx Pharmaceuticals Inc

Table of Contents

Table of Contents

Introduction

Chikungunya Fever - Overview

Chikungunya Fever - Therapeutics Development

Chikungunya Fever - Therapeutics Assessment

Chikungunya Fever - Companies Involved in Therapeutics Development

Chikungunya Fever - Drug Profiles

Chikungunya Fever - Dormant Projects

Chikungunya Fever - Product Development Milestones

Appendix

List of Tables

List of Tables

Number of Products under Development for Chikungunya Fever, H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020

Number of Products under Development by Universities/Institutes, H1 2020

Products under Development by Companies, H1 2020

Products under Development by Companies, H1 2020 (Contd..1), H1 2020

Products under Development by Universities/Institutes, H1 2020

Number of Products by Stage and Target, H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020

Number of Products by Stage and Route of Administration, H1 2020

Number of Products by Stage and Molecule Type, H1 2020

Chikungunya Fever – Pipeline by Activirosomes Ltd, H1 2020

Chikungunya Fever – Pipeline by Bharat Biotech Ltd, H1 2020

Chikungunya Fever – Pipeline by Bow Therapeutics, H1 2020

Chikungunya Fever – Pipeline by Ciloa, H1 2020

Chikungunya Fever – Pipeline by Clayton Biotechnologies Inc, H1 2020

Chikungunya Fever – Pipeline by Emergent BioSolutions Inc, H1 2020

Chikungunya Fever – Pipeline by Emergex Vaccines Ltd, H1 2020

Chikungunya Fever – Pipeline by Ennaid Therapeutics LLC, H1 2020

Chikungunya Fever – Pipeline by Etubics Corp, H1 2020

Chikungunya Fever – Pipeline by Hawaii Biotech Inc, H1 2020

Chikungunya Fever – Pipeline by HSRx Group, H1 2020

Chikungunya Fever – Pipeline by Immunomodulation Inc, H1 2020

Chikungunya Fever – Pipeline by Imophoron Ltd, H1 2020

Chikungunya Fever – Pipeline by Indian Immunologicals Ltd, H1 2020

Chikungunya Fever – Pipeline by Inovio Pharmaceuticals Inc, H1 2020

Chikungunya Fever – Pipeline by Integral Molecular Inc, H1 2020

Chikungunya Fever – Pipeline by Integrated BioTherapeutics Inc, H1 2020

Chikungunya Fever – Pipeline by Medigen Inc, H1 2020

Chikungunya Fever – Pipeline by Moderna Inc, H1 2020

Chikungunya Fever – Pipeline by Najit Technologies Inc, H1 2020

Chikungunya Fever – Pipeline by Pai Life Sciences Inc, H1 2020

Chikungunya Fever – Pipeline by Paradigm Biopharmaceuticals Ltd, H1 2020

Chikungunya Fever – Pipeline by Precision Virologics Inc, H1 2020

Chikungunya Fever – Pipeline by Profectus BioSciences Inc, H1 2020

Chikungunya Fever – Pipeline by ProtInhi BV, H1 2020

Chikungunya Fever – Pipeline by Riboscience LLC, H1 2020

Chikungunya Fever – Pipeline by Ridgeback Biotherapeutics LP, H1 2020

Chikungunya Fever – Pipeline by Sementis Ltd, H1 2020

Chikungunya Fever – Pipeline by Shionogi & Co Ltd, H1 2020

Chikungunya Fever – Pipeline by Takeda Pharmaceutical Co Ltd, H1 2020

Chikungunya Fever – Pipeline by Themis Bioscience GmbH, H1 2020

Chikungunya Fever – Pipeline by Valneva SE, H1 2020

Chikungunya Fever – Pipeline by Vaxart Inc, H1 2020

Chikungunya Fever – Pipeline by VenatoRx Pharmaceuticals Inc, H1 2020

Chikungunya Fever – Dormant Projects, H1 2020

Chikungunya Fever – Dormant Projects, H1 2020 (Contd..1), H1 2020

List of Figures

List of Figures

Number of Products under Development for Chikungunya Fever, H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products under Development by Universities/Institutes, H1 2020

Number of Products by Top 10 Targets, H1 2020

Number of Products by Stage and Top 10 Targets, H1 2020

Number of Products by Top 10 Mechanism of Actions, H1 2020

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020

Number of Products by Routes of Administration, H1 2020

Number of Products by Stage and Top 10 Routes of Administration, H1 2020

Number of Products by Top 10 Molecule Types, H1 2020

Number of Products by Stage and Top 10 Molecule Types, H1 2020

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports